Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Crescent Biopharma (CBIO) Operating Expenses (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Operating Expenses for 11 consecutive years, with $102.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses changed N/A to $102.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $151.6 million through Dec 2025, changed N/A year-over-year, with the annual reading at $163.5 million for FY2025, 308.29% up from the prior year.
  • Operating Expenses for Q4 2025 was $102.3 million at Crescent Biopharma, up from $25.9 million in the prior quarter.
  • The five-year high for Operating Expenses was $102.3 million in Q4 2025, with the low at $2.4 million in Q1 2025.
  • Average Operating Expenses over 5 years is $17.2 million, with a median of $11.1 million recorded in 2024.
  • Peak annual rise in Operating Expenses hit 883.85% in 2025, while the deepest fall reached 78.42% in 2025.
  • Over 5 years, Operating Expenses stood at $17.4 million in 2021, then plummeted by 39.1% to $10.6 million in 2022, then fell by 9.62% to $9.6 million in 2023, then plummeted by 72.6% to $2.6 million in 2024, then skyrocketed by 3789.62% to $102.3 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $102.3 million, $25.9 million, and $21.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.